UTv Videos

INVITE is a 2-part clinical trial designed to evaluate the safety, feasibility, and patient experience of administering intravesical bladder cancer therapies in the home.

One notable trend is the shift of therapies originally reserved for heavily pretreated, castration-resistant prostate cancer into earlier phases of disease.

The ENLIGHTED trial is evaluating the safety and efficacy of padeliporfin vascular targeted photodynamic therapy for low-grade upper tract urothelial carcinoma.

The 510(k) clearance was supported by 12-month data from the VAPOR 2 trial, which were presented at the 2025 SUO Annual Meeting.

Sameena A. Rahman, MD, emphasizes that menopause care requires precision medicine rather than a one-size-fits-all approach.

Leila Momtazi-Mar notes that although some studies suggest a decline in retrieval rates after age 40, this association remains preliminary.

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses key findings from the phase 3 POTOMAC trial and other studies of BCG/ICI combinations in high-risk NMIBC.

Mills describes TRT not merely as a prescription but as an ongoing therapeutic relationship aimed at comprehensive, long-term wellness.

Beyond rectal protection, rectal spacers may facilitate curative radiation dosing and reduce the likelihood of local recurrence.

Once patients are ready to explore treatment, Fosnight stresses the importance of shared decision-making.

The data, presented at ESMO, support a role for gemcitabine intravesical system plus cetrelimab in MIBC.

Nicholas Deebel, MD, shared key takeaways from a recent review outlining the current evidence on post-vasectomy pain syndrome.

A key finding was that 86% of patients required no additional therapy after receiving nadofaragene.

Muhammed A. Moukhtar Hammad, MBBCh, highlights ongoing work to develop a machine learning model to predict inflatable penile prothesis complications.

Rahul Aggarwal, MD, shares key takeaways from the PRESTO trial as well as remaining questions in the field.

Stacy Loeb, MD, MSc, PhD (Hon), debunks common misconceptions about prostate cancer and offers suggestions as to how urologists can help push back against misinformation.

Matthew A. Love, MD, discusses key efficiency and safety considerations for the SURE procedure.

One particularly striking finding from KEYNOTE-905/EV-303 is the nearly 60% pathologic complete response rate.

The phase 3 AMPLITUDE trial evaluated the safety and efficacy of adding niraparib to abiraterone acetate plus prednisone in patients with mHSPC.

Data suggested that most patients do not have a preference on the gender of the urologist who is providing their vasectomy care.

Jason M. Hafron, MD, CMO, touches on the growing shift toward biomarker-driven therapy in advanced prostate cancer.

Joshua J. Meeks, MD, PhD, highlights that collaboration between urologists and medical oncologists has become essential.

Jason M. Hafron, MD, recaps noteworthy prostate cancer research from ESMO 2025.

Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.

Stacy Loeb, MD, shares key takeaways from her LUGPA 2025 session, “Current state of prostate cancer screening.”

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

Andrew W. Hahn, MD, highlights safety and tolerability data on lenvatinib/everolimus vs cabozantinib for metastatic ccRCC.